Better treatments are needed for small cell lung cancer (SCLC), an aggressive disease with poor prognosis (5-year survival rate less than 2%). Virtually all SCLCs have inactivating mutations in the same two genes, RB1 and TP53, but all efforts to design drugs … more >
Research Roundups > | News Releases >